Services: Cellules souches et exosomes

What It Is

A stem cell can copy itself and become other kinds of cell, the raw material the body uses to repair tissue. The word covers two very different things. The first is a narrow, approved field of medicine. Blood-forming stem-cell transplants have cured blood cancers for more than 50 years, and cultured limbal stem cells can rebuild a cornea destroyed by a burn. The second, a consumer marketplace, sells injections outside that approved field.

Stem Cells, Exosomes, and What the Clinics Inject

1Flexible cells versus limited ones

Embryonic and certain lab-reprogrammed cells can become almost any tissue. The adult cells used in most clinics, mainly mesenchymal stromal cells taken from body fat or bone marrow, are far more limited in what they can turn into.

2What the clinics inject

Direct-to-consumer clinics draw these cells from a patient, or use cells from donated cord blood. They inject them into a joint, a vein, or, in some cases, the eye. The cells are frequently not characterized or standardized, so what is in the syringe varies.

3Where exosomes fit

Cells release exosomes, tiny membrane vesicles, to signal to one another. Products marketed as exosome therapy are cell-free preparations promoted as the next step beyond stem cells.

How It Works

The picture sold to patients is simple. Injected cells travel to the damage, engraft, and become the tissue a patient hopes to regrow: cartilage, nerve, or retina. For the mesenchymal stromal cells most clinics use, that is largely not what happens. These cells rarely engraft or turn into new tissue after an injection. Where they do act, the effect is paracrine and short-lived. For a brief window they release signaling molecules that calm inflammation, then the body clears them. Arnold Caplan, who named the field, has argued the cells were misnamed, because they signal to nearby tissue instead of building it.

A few of these treatments are settled, curative medicine. Most are sold before any trial has shown they work.

What Changed

For decades, stem-cell medicine meant transplant and a short list of established procedures. Then a consumer market formed beside it. A 2016 survey counted hundreds of United States businesses marketing stem-cell interventions directly to consumers for a wide range of conditions. Later reviews describe a sector that kept expanding and added exosome offerings.

Where The Research Stands

Two of these uses are settled, curative medicine. The others rest on far less: small trials, or none at all.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Cancer Risk And Outcome

Bone marrow and blood stem-cell transplant cures blood cancers, standard care over fifty yearsStrong

In plain terms

Bone marrow and blood stem-cell transplant is a cure for blood cancers like leukemia, and it has been standard medical care for decades.

In detail

Hematopoietic stem-cell transplant, using blood-forming stem cells from bone marrow, circulating blood or cord blood to reconstitute the blood and immune system, is established curative therapy for leukemia, lymphoma and other blood and marrow disorders, with more than fifty years of clinical use. This is a demanding hospital treatment with significant risks of its own, and it is a specific approved use that does not extend to the aging, joint and chronic-disease injections marketed by direct-to-consumer clinics.

The study · 1

Copelan, Hematopoietic stem-cell transplantation · N Engl J Med 2006;354(17):1813-1826

Vision

Cultured limbal stem cells restored a clear corneal surface in 76.6% of eyes across 112 burn patientsModerate

In plain terms

Stem cells taken from the rim of the patient's own eye, grown in the lab and transplanted back, permanently rebuilt a clear corneal surface in about three-quarters of eyes blinded by burns.

In detail

In 112 patients with corneas destroyed mostly by chemical or thermal burns, treatment with cultured autologous limbal stem cells restored a permanent, transparent, self-renewing corneal epithelium in 76.6% of eyes, with successes stable over long-term follow-up and failures occurring within the first year. This is a specific treatment for burn-related limbal stem-cell deficiency delivered in a specialist setting, not evidence for the general regenerative injections sold by clinics, and it was an uncontrolled case series, not a randomized trial.

The study · 1

Rama et al., Limbal stem-cell therapy and long-term corneal regeneration · N Engl J Med 2010;363(2):147-155

How it works

Les cellules mésenchymateuses injectées agissent par une brève signalisation paracrine, et non en devenant un nouveau tissuModerate · mixed

In plain terms

Les cellules souches habituellement injectées en clinique ne s'implantent pas durablement et ne se transforment pas en nouveau cartilage ou en nerf. Au mieux, elles libèrent brièvement des substances de signalisation avant d'être éliminées, ce qui est différent de la reconstruction tissulaire que suggère le marketing.

In detail

Les cellules stromales mésenchymateuses, les cellules le plus souvent injectées en clinique, s'implantent ou se différencient rarement en nouveau tissu après injection ; lorsqu'elles agissent, leur effet est principalement paracrine et transitoire, libérant des molécules de signalisation qui modulent l'inflammation avant d'être éliminées, ce qui est une action différente du remplacement tissulaire suggéré par leur marketing. Ceci décrit la compréhension dominante des cellules stromales mésenchymateuses adultes et ne s'étend pas aux cellules embryonnaires ou reprogrammées, et l'intensité et la durée de l'effet de signalisation varient selon la source et la préparation cellulaires.

The study · 1

Caplan, Mesenchymal Stem Cells: Time to Change the Name! · Stem Cells Transl Med 2017;6(6):1445-1451

Joint And Arthritis Pain

Les injections de cellules souches au genou ont modestement soulagé la douleur et amélioré la fonction dans quatre petits essais portant sur 138 patientsPreliminary

In plain terms

Pour les genoux arthritiques, quatre petits essais randomisés portant sur 138 patients, regroupés, montrent que les injections de cellules souches améliorent modestement la douleur et la fonction, mais les études sont incohérentes et n'ont pas démontré de supériorité par rapport à des traitements standards moins coûteux.

In detail

Une méta-analyse regroupant quatre essais contrôlés randomisés sur l'injection de cellules stromales mésenchymateuses dérivées du tissu adipeux pour l'arthrose du genou, totalisant 138 patients, a constaté une amélioration de la douleur et de la fonction à 12 mois de suivi, mais issue de petits essais très hétérogènes quant à la source et à la préparation cellulaires et à suivi court, et sans démontrer de supériorité par rapport aux options établies moins coûteuses. Les essais sont de petite taille, hétérogènes quant à la source et à la préparation des cellules, et de suivi court, et aucun n'établit que ces injections surpassent la kinésithérapie ou les injections standards qui coûtent une fraction de leur prix.

The study · 1

Issa et al., The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials · Ther Adv Musculoskelet Dis 2022;14:1759720X221146005

The Established Uses

Hematopoietic stem-cell transplant rebuilds a patient's blood and immune system from blood-forming stem cells taken from bone marrow, circulating blood, or cord blood. It is standard curative care for leukemia, lymphoma, and other blood disorders. Cultured limbal stem cells are the other settled use. Across 112 patients whose corneas were destroyed mostly by chemical or thermal burns, cultured limbal cells rebuilt a permanent, self-renewing corneal surface in 76.6% of eyes. Those successes held over long follow-up. A small set of other cell products also carries regulatory approval for defined conditions. Each of these uses is precise, tested, and delivered under regulatory oversight.

The Direct-to-Consumer Market

Most of these clinic products are investigational: unapproved for the conditions advertised, with a clinical trial as the expected next step. Many are sold as finished treatments instead. Clinics market them as broadly effective and blame slow approval for the missing evidence. The same product is sold for four unrelated conditions, aging, joints, autism, and multiple sclerosis, and no completed trial supports any of them.

The Documented Harms

Three harms are on record, each from injectable biological products sold outside the testing that approved treatments carry. In one case series, a clinic injected fat-derived cells into both eyes of three patients in a single session for macular degeneration, and all three were blinded. A product made from donated cord blood carried bacteria and caused bloodstream infections in the patients who received it. Cash-paid clinics have also triggered dangerous joint infections.

The Orthopedic Evidence

The knee is where clinic claims are strongest and most common. The cells clinics inject have been tested for knee osteoarthritis in several small randomized trials. A meta-analysis of those trials found a real improvement in pain and function. The signal is limited: the trials are small, they vary widely in how the cells are sourced and prepared, and follow-up is short. They have not shown durable superiority over standard options such as physical therapy or standard injections in adequately powered head-to-head trials. For a knee, the benefit is modest and preliminary. Physical therapy and standard care stay the tested option.

Exosomes

Exosomes reached clinics last, and scientifically they are the most interesting part of the field. The rationale follows from the cell biology. If a mesenchymal cell mostly works by sending chemical messages, those messages, packaged in exosomes, might be delivered on their own. As cell-free preparations of signaling vesicles, they are a genuine and promising research subject. Scientists who study extracellular vesicles have published position papers calling exosome medicines premature and unconfirmed. The block is the absence of a standardized way to define a product or measure its dose. No exosome product is approved for the anti-aging and regenerative uses clinics advertise. Preparations sold as exosome therapy raise the same contamination concerns as the cell products that caused infections.

Go Deeper

• The biology of aging: the drivers behind the renewal that stem-cell and exosome clinics promise to restore.
• Rapamycin: another field where a few approved drugs sit beside a large off-label market, and how to keep the two apart.
• Senolytics: a different anti-aging approach, aimed at clearing worn-out cells instead of adding new ones.
• Peptides: a neighboring market of injectable products sold ahead of the trials, with the same approval gap.

The Chinese Medicine View

Stem cells and exosomes come from modern cell biology, isolated and named in the 20th and 21st centuries; no classical Chinese text describes them, and no traditional formula contains them.

Chinese medicine centers renewal and constitutional reserve on the Kidney and its store of Jing, the essence. The Kidney holds Jing as a deep reserve, present at birth and drawn down across a lifetime. The classics describe its decline in signs close to what modern medicine calls aging.

Building the body up, what the tradition calls tonifying, is warranted only when there is a true deficiency and the person can assimilate what is given. The classics warn that over-treating a depleted body weakens it further.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Seuls quelques produits cellulaires sont approuvés ; la plupart des produits régénératifs commercialisés restent expérimentaux

Under the regulatory framework for cell-based products, only a small number of cell therapies are approved for defined conditions, while most products marketed for regenerative and anti-aging uses are investigational and are expected to be studied in clinical trials, not sold as treatments. La frontière entre un produit approuvé et un produit expérimental relève d'un jugement réglementaire qui continue d'être contesté et appliqué de façon inégale, de sorte qu'un produit présent sur le marché n'est pas nécessairement un produit approuvé.Marks and Gottlieb, Balancing Safety and Innovation for Cell-Based Regenerative Medicine

Des centaines de cliniques américaines vendent des injections de cellules souches et d'exosomes pour des usages que ces produits ne sont pas approuvés à traiter

Une enquête de 2016 menée aux États-Unis a identifié des centaines d'entreprises commercialisant des interventions à base de cellules souches directement aux consommateurs pour un large éventail d'affections, et des analyses ultérieures décrivent un secteur qui a continué de croître et d'ajouter des offres d'exosomes, largement en dehors des indications pour lesquelles les produits sont approuvés. Ces chiffres proviennent de l'automarketing des cliniques et de leur présence en ligne, de sorte que le nombre réel d'entreprises et ce qu'elles proposent réellement peuvent être sous-estimés ou mal représentés, mais l'ampleur du marché ne fait aucun doute.Turner and Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryBrinsfield et al., The evolution and ongoing challenge of unproven cell-based interventions

Trois femmes sont passées d'une vision quasi normale à la cécité après l'injection de cellules dérivées de graisse dans les deux yeux

Trois patients ont subi une perte de vision bilatérale sévère après qu'une clinique a injecté des cellules souches autologues dérivées du tissu adipeux dans les deux yeux pour une dégénérescence maculaire liée à l'âge ; l'acuité visuelle est passée d'une fourchette pré-injection de 20/30 à 20/200 à une fourchette de 20/200 à absence de perception lumineuse un an plus tard, avec des complications incluant hypertension oculaire, rétinopathie hémorragique et décollement de rétine. Il s'agit d'une série de cas portant sur trois patientes, ce qui établit qu'un préjudice grave peut survenir, non un taux, et l'injection a été réalisée dans les deux yeux le même jour, ce qui a supprimé tout œil sain de secours.Kuriyan et al., Vision Loss after Intravitreal Injection of Autologous Stem Cells for AMD

Infections sanguines retracées à un produit de sang de cordon contaminé par des bactéries

Des patients ayant reçu un produit dérivé de sang de cordon ombilical pour des usages autres que la reconstitution sanguine ou immunitaire ont développé des infections sanguines que l'enquête de santé publique a retracées à une contamination bactérienne du produit lui-même. Il s'agissait d'une enquête sur une flambée liée à un produit contaminé spécifique, non d'une étude d'un taux à travers toutes les cliniques, et cela reflète le risque de contamination des produits fabriqués et manipulés en dehors d'une fabrication approuvée.Perkins et al., Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products

Graves infections articulaires nécessitant une intervention chirurgicale après des injections intra-articulaires dans des cliniques payantes

Des cas ont été rapportés de graves infections articulaires nécessitant un traitement chirurgical après que des patients ont reçu des injections intra-articulaires de cellules souches dans des cliniques payantes pour des plaintes articulaires. Il s'agit de rapports de cas individuels, non d'un taux d'infection mesuré, mais ils documentent que les produits injectés provenant de cliniques non réglementées peuvent provoquer une infection articulaire.Taliaferro et al., Cash-Based Stem-Cell Clinics: The Modern Day Snake Oil Salesman? A Report of Two Cases

Aucun produit à base d'exosomes n'est approuvé, et aucune norme ne définit encore une dose ou une puissance de produit

Des prises de position de chercheurs en vésicules extracellulaires décrivent le développement des thérapeutiques à base d'exosomes comme précoce et inachevé, freiné par l'absence de méthodes standardisées permettant de définir l'identité du produit, de quantifier la dose et de confirmer la puissance, et aucun produit à base d'exosomes n'est approuvé pour les usages régénératifs et anti-âge que les cliniques annoncent. Les thérapeutiques à base d'exosomes constituent un domaine de recherche légitime et actif, de sorte que ceci décrit leur statut de développement et réglementaire précoce, non un verdict sur leur potentiel final.Lener et al., Applying extracellular vesicles based therapeutics in clinical trials: an ISEV position paperSilva et al., Development of extracellular vesicle-based medicinal products: a position paper

Le tourisme des cellules souches a causé des complications graves, y compris neurologiques, et supprime les garde-fous

Des revues critiques du tourisme international des cellules souches documentent des complications graves chez des patients qui se rendent à l'étranger pour des interventions par cellules souches non réglementées, y compris des complications neurologiques, et notent l'absence de la surveillance de fabrication, des normes de consentement et du suivi qu'offre une prise en charge réglementée. Les preuves proviennent de revues et de cas rapportés, non d'un suivi systématique des résultats, car ces interventions sont réalisées en dehors des systèmes qui enregistreraient les complications, ce qui fait partie du risque lui-même.Lyons et al., International stem cell tourism: a critical literature review and evidence-based recommendationsJulian et al., The Growing Reality of the Neurological Complications of Global Stem Cell Tourism

Approval here is narrow

Hematopoietic transplant and limbal cell therapy are established care. The injections sold for anti-aging, orthopedic, and chronic-disease uses are not approved for those uses.

Injections near the eye can blind

An injection into or around the eye carries a risk of severe, permanent vision loss, and the eye cannot regrow tissue it loses.

Contaminated products cause infections

Products made and handled outside approved manufacturing can be contaminated. An injected infection can be limb- or life-threatening.

Treatment abroad removes the safeguards

Traveling abroad for stem-cell treatment can mean an injection with none of the manufacturing oversight, consent standards, or follow-up of regulated care. Reviews document serious complications, including neurological ones, in returning patients. A treatment you can only get abroad is usually unavailable at home because it has not passed the required testing.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Which of these are approved treatments?

Hematopoietic transplant for blood cancers and cultured limbal stem cells for a burned cornea are approved and regulated. The injections marketed for aging and worn joints are not. The dividing line is regulatory approval and evidence from a finished trial.

Can stem cells reverse aging or regrow a joint?

No completed trial shows either claim. Both come from marketing, and no results in patients back them.

Why does it cost thousands of dollars if it is not approved?

Products sold outside the approval framework are cash services; insurance and regulators cover only licensed medicines. A high price and a professional setting can look like proof of value on their own.

Is it safe to get an injection at a clinic?

The known safety problems trace to products made and injected outside regulated manufacturing. These products skip the FDA oversight that approved treatments clear, and contamination is the real risk.